Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. NICE technology appraisal guidance 181 (2009).
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal).NICE technology appraisal guidance 148 (2008).
The diagnosis and treatment of lung cancer. NICE clinical guideline 24 (2005). [Replaced by NICE clinical guideline 121]
NICE is developing the following guidance (details available from the NICE website):
Cetuximab for the treatment of advanced non-small cell lung cancer. NICE technology appraisal guidance. Publication date to be confirmed.